Portola Pharmaceuticals

Advancing therapeutics for thrombosis and hematologic diseases

Portola (NASDAQ: PTLA) was founded in 2003 to develop and commercialize novel therapeutics for cardiovascular and hematologic diseases. The company's pipeline includes: 1) betrixaban, an oral once-daily Factor Xa inhibitor to prevent venous thromboembolism; 2) adnexanet alfa, a first-in-class recombinant, modified Factor Xa that is being developed as a Factor Xa inhibitor antidote; and 3) cerdulatinib, a dual inhibitor of Syk and JAK pathways for hematologic malignanices. Portola completed its IPO on NASDAQ in 2013.


IPO in 2013 (NASDAQ: PTLA)

Year of Investment



Life Sciences


Development-Stage Therapeutics


South San Francisco, California